The stock of Immunomedics, Inc (NASDAQ:IMMU) closed at $12.64 gaining 7.21% in yesterday’s trading session. This provider made an announcement regarding the encouraging interim results from labetuzumab govitecan (IMMU-130).
In the heavily-pretreated patients with metastatic colorectal cancer (mCRC), this candidate will be evaluated as a single agent.
On Aug 21, the provider’s shares closed 7% higher and that was after the announcement of the news. So far this year, the shares of the company have returned 145.5%, which is indeed an over-performance in the industry which gained 5.2% in that period.
The once weekly 8mg or 10 mg dose of IMMU-30 for those persons that received Pfizer Inc’s PFE Camptosar therapy is what the study is embarking on at the moment and it hopes to carry out a proper evaluation within a short period of time.
The median progression free survival (PFS) arrived at was 3.6 months for 10 mg and 4.6 months for 8mg dosage. Asides from that, the median overall survivals (OS) showcased by the candidate was 6.4 months (10mg) and 7.5 months (8mg).
Bayer AG’s BAYRY Stivarga had earlier administered treatment to a subset of 23 patients. In this particular subset, the median OS and PFS achieved by the candidate were 4 months and 6.7 months, respectively. That was a lot much better than Stivarga’s OS and PFS.
Sacituzumab govitecan (IMMU-132) is the other ADC that the provider is developing for patients with relapsed/refractive, metastatic triple-negative breast cancer. The company is reminding all its investors on the great need for them to understand that IMMU-132 enjoys Breakthrough Therapy Designation in the U.S. At the moment, it has plans underway to file a Biologics License Application.
The main reason behind the development of IMMU-132 was to help treat a wide array of the metastatic solid tumors. There is also an ongoing evaluation of the IMMU-140, another ADC candidate for the liquid and solid cancers.
The company’s spokesperson opined, “Immunomedicas is committed to delivering to stockholders the significant value created by a number of agreements that it has signed into lately.”
